ReacX is a development-stage biotechnology company developing proprietary therapeutics using its clinically proven ProNeura^® long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating  a number of chronic conditions where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.

ProNeura consists of a small, semi-rigid, flexible implant made from a mixture of EVA (ethylene-vinyl acetate) and a drug substance. The resulting product is a solid matrix implant that is administered subdermally, normally in the inner upper arm, in a brief, outpatient procedure and is removed in a similar manner at the end of the treatment period. These procedures may be performed by trained health care providers, or HCPs, including licensed and surgically qualified physicians, nurse practitioners, and physician’s assistants in a HCP’s office or other clinical setting.

The first product based on ProNeura technology was Probuphine® (buprenorphine) implant. Probuphine was approved in the United States, Canada and the European Union, or EU, for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 mg or less a day of oral buprenorphine, In October 2020, this product was withdrawn from the market as the company marketing this product decided to wind down their commercialization activities. ReacX Pharmaceuticals has acquired Probuphine and the Proneura technology, and is looking forward to relaunching Probuphine and to continuing the development of ProNeura technology-based products for other therapeutic indications.